Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease
Ming‐Han Chen, I‐Cheng Lee, Ming‐Huang Chen, Ming‐Chih Hou, Chang‐Youh Tsai, Yi‐Hsiang Huang
Topics & Concepts
MedicineHBsAgAbataceptInternal medicineRituximabHepatitis B virusRheumatoid arthritisSeroconversionHepatitis BGastroenterologyImmunologyAntibodyVirusLymphomaHepatitis B Virus StudiesRheumatoid Arthritis Research and TherapiesHepatitis C virus research